|
|
Volumn 97, Issue 5, 2005, Pages 336-337
|
|
Vascular normalization: Study examines how antiangiogenesis therapies work
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY DC101;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
VASCULOTROPIN ANTIBODY;
VASCULOTROPIN INHIBITOR;
VASCULOTROPIN RECEPTOR 2;
BEVACIZUMAB;
ANGIOGENESIS;
CANCER;
CANCER RADIOTHERAPY;
DRUG MECHANISM;
GAMMA RADIATION;
HUMAN;
HYPOXEMIA;
NONHUMAN;
NOTE;
PERICYTE;
PRIORITY JOURNAL;
TISSUE OXYGENATION;
ANIMAL;
ARTICLE;
CELL HYPOXIA;
CLINICAL TRIAL;
DRUG ADMINISTRATION;
DRUG EFFECT;
NEOPLASM;
NEOVASCULARIZATION (PATHOLOGY);
TIME;
VASCULARIZATION;
XENOGRAFT;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTIBODIES, MONOCLONAL;
CELL HYPOXIA;
CLINICAL TRIALS;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
NEOPLASMS;
NEOVASCULARIZATION, PATHOLOGIC;
TIME FACTORS;
TRANSPLANTATION, HETEROLOGOUS;
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;
|
|
EID: 14544280657
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/97.5.336 Document Type: Note |
|
Times cited : (19)
|
|
References (0)
|